Stock Track | West Pharmaceutical Stock Plummets 24.11% as 2025 Outlook Disappoints on Destocking, Dollar Strength

Stock Track

Feb 13, 2025

West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.

The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.

West Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that "the impact of destocking continues to moderate" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130013047"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130013047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130013047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130013047","market":"hk","top_or_hot":-1,"title":"Stock Track | West Pharmaceutical Stock Plummets 24.11% as 2025 Outlook Disappoints on Destocking, Dollar Strength","media":"Stock Track","content":"<p>West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.</p>\n\n<p>The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.</p>\n\n<p>West Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that \"the impact of destocking continues to moderate\" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | West Pharmaceutical Stock Plummets 24.11% as 2025 Outlook Disappoints on Destocking, Dollar Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | West Pharmaceutical Stock Plummets 24.11% as 2025 Outlook Disappoints on Destocking, Dollar Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.</p>\n\n<p>The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.</p>\n\n<p>West Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that \"the impact of destocking continues to moderate\" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WST","symbol_name":"West Pharmaceutical Services Inc","start_time":0,"source_url":"","article_id":"1130013047","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130013047","pubTimestamp":1739458203,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"West Pharmaceutical  stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.0","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WST":"West Pharmaceutical Services Inc"},"translate_title":"股票赛道西部制药股价暴跌24.11%，2025年去库存和美元走强前景令人失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WST":1},"content_text":"West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.\nThe medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.\nWest Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that \"the impact of destocking continues to moderate\" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}